Occurrence Rates of Delirium in Brain Tumor Patients: A Systematic Review and Meta-Analysis
Auftreten von Delir bei Patient:innen mit Hirntumoren: systematische Übersicht und Metaanalyse
Cancers · 15.06.2025 · 17 (12) · 1998
DOI: 10.3390/cancers17121998 ↗Auf einen Blick
Eine systematische Übersicht und Metaanalyse zeigte bei hospitalisierten Patient:innen mit Hirntumoren ein häufiges Delir. Die Häufigkeit war bei Hirnmetastasen und frontotemporalen Tumoren höher.
Fragestellung
Wie hoch ist das Auftreten von Delir bei hospitalisierten Patient:innen mit Hirntumoren?
Methode
Systematische Übersicht und Metaanalyse von Studien zu hospitalisierten Patient:innen mit Hirntumoren; Suche in PubMed, Scopus und Web of Science von 1. Januar 1999 bis 12. Juli 2024.
Ergebnisse
27 Studien mit 35.958 Patient:innen. Gesamtauftreten 0,17 (95 %-KI 0,11–0,24); niedriggradige Gliome 0,10, hochgradige Gliome 0,21, Hirnmetastasen 0,31. Frontallappen RR 3,08, Temporallappen RR 2,88; hypoaktives Delir RR 1,61; 4,62 Tage längerer Aufenthalt.
Einschränkungen
Das Auftreten in der Literatur war sehr heterogen.
Schlussfolgerung der Autor:innen
Die Autor:innen bestätigten hohe Delir-Raten bei hospitalisierten Patient:innen mit Hirntumoren. Bei Hirnmetastasen und frontotemporalen Tumoren war das Auftreten höher.
Kernaussagen
- Gesamtauftreten von Delir: 0,17 (95 %-KI 0,11–0,24)
- Höhere Raten bei Hirnmetastasen als bei Gliomen
- Delir war mit 4,62 zusätzlichen hospitalisierten Tagen verbunden
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.06.2025. Verfasst von Zachary Tentor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NCATS NIH HHS, American Academy of Neurology.
Themen: Delir
Abstract (Originalsprache)
Background
The occurrence (incidence or prevalence) of delirium in brain tumors is unknown, yet delirium is associated with increased morbidity and mortality and worse quality of life. We conducted a systematic review and meta-analysis to determine the occurrence of delirium in hospitalized patients with brain tumors.
Methods
PubMed, Scopus, and Web of Science were systematically searched for papers from 1 January 1999 to 12 July 2024, including references from texts. Cross-sectional, prospective, and other cohort study designs were included, and individual case reports, case series, editorials, and reviews were excluded. The included papers were scored using a validated sensitivity analysis tool and tested for quality and bias using funnel plots and Egger’s test. We used random effects models for the summary estimates. We performed subgroup analyses by tumor type, tumor location, delirium subtype, and length of stay.
Results
Of the 452 studies screened, 27 were included, representing 35,958 patients. The overall occurrence of delirium was 0.17 (95% CI [0.11–0.24]). Delirium occurrence in patients with low-grade gliomas, high-grade gliomas, and brain metastases was 0.10 [0.06–0.16], 0.21 [0.10–0.40], and 0.31 [0.16–0.50], respectively. Compared to the occipital lobe, there was a higher occurrence of delirium for tumors in the frontal (RR 3.08 [1.35–8.22]) and temporal lobes (RR 2.88 [1.22–7.93]). The patients were more likely to have hypoactive (RR 1.61 [1.30; 1.98]) than hyperactive delirium. Delirium was associated with 4.62 additional hospitalized days compared to those without delirium (CI [3.23–6.01]).
Discussion
We confirmed high occurrence rates of delirium in patients hospitalized with brain tumors. Patients with brain metastases had a higher occurrence of delirium compared to patients with gliomas, and delirium occurrence rates were higher in patients with frontotemporal tumors. Delirium occurrence rates in the literature are very heterogeneous and point toward a need for tailored assessments in patients with brain tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- School of Medicine, University of Navarra, 31009 Pamplona, Spain.
- Department of Neurology, Northwestern University, Chicago, IL 60611, USA.
- Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.
- Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
ORCID-Profile: Paul J Miller, Joshua Davis, Erika Juarez Martinez, John Y Rhee
Förderung
- NIA NIH HHS
- NCATS NIH HHS
- American Academy of Neurology
- American Academy of Neurology Clinical Research Training Scholarship
- Harvard Catalyst|The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health)
- Harvard University and its affiliated academic healthcare centers
Zitieren
APA
Tentor, Z., Finnemore, A., Miller, P. J., Davis, J., Juarez Martinez, E., Lindvall, C., Kimchi, E. Y., & Rhee, J. Y. (2025). Occurrence Rates of Delirium in Brain Tumor Patients: A Systematic Review and Meta-Analysis. Cancers, 17(12), 1998. https://doi.org/10.3390/cancers17121998
Vancouver
Tentor Z, Finnemore A, Miller PJ, Davis J, Juarez Martinez E, Lindvall C, et al. Occurrence Rates of Delirium in Brain Tumor Patients: A Systematic Review and Meta-Analysis. Cancers. 2025;17(12):1998. doi:10.3390/cancers17121998
BibTeX
@article{Tentor2025,
author = {Tentor, Zachary and Finnemore, Alexander and Miller, Paul J and Davis, Joshua and Juarez Martinez, Erika and Lindvall, Charlotta and Kimchi, Eyal Y and Rhee, John Y},
title = {Occurrence Rates of Delirium in Brain Tumor Patients: A Systematic Review and Meta-Analysis},
journal = {Cancers},
year = {2025},
volume = {17},
number = {12},
pages = {1998},
doi = {10.3390/cancers17121998}
}
EUVIMED